anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a Bluetooth pacifier for infants, toddlers, and children. More specifically, the Bluetooth pacifier includes a nipple, a collar and a handle. The Bluetooth pacifier includes an integrated Bluetooth microchip and a micro-USB charging port in the collar. The Bluetooth microchip periodically transmits Bluetooth Low Energy signals (BLE) to a paired electronic device. A software application installed in the electronic device processes the received BLE signals and associated RSSI values of the BLE signals for location tracking of the pacifier. When the pacifier and the electronic device are not in BLE range, the software application stores the last recorded (i.e. past-time) location of the pacifier. The micro-USB charger can be used for attaching a USB charger.
Use the test products, ProLon(TM) Fasting Mimicking Diet, during the scheduled 5-day period in place of the usual meals (breakfast, lunch, dinner, snack) according to the instructions. Use the test product for 5 days for 3 cycles, beginning on day 1, day 30, and day 60.
The invention disclosed herein is directed to compounds of Formula (la) and (lb) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticd leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (la) or (lb), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPARa and PPARd. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a herapeutically effective amount of a dual antagonist of PPARa and PPARd.
Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
Context: Adolescents and young adults (AYA) with spina bifida (SB) are more susceptible to obesity due to impaired mobility. There is limited access to physical activity for this population.Objective: The primary aim of this study was to evaluate the feasibility of a mobile health app in a weight management program for AYA with SB. This was determined by measuring program adherence, active use of the app (defined as ≥3 uses per week), and user rating of the Pt Pal™ mobile app. Secondary outcomes were changes in BMI, quality of life, and health behavior, and the number of active participants over time.Methods: Patients from the SB Clinic of a large metropolitan hospital between the ages of 11-21 years and overweight were invited to participate. The program consisted of group nutrition sessions and an individualized exercise plan using a mobile app with coaching. Outcome measures were program adherence, changes in BMI, and validated survey responses. Descriptive statistical analysis was performed.Results: Fifteen participants enrolled, and ten participants completed the program. Five of the ten participants attended the nutrition sessions. The number of active app users declined after the first week. Seventy percent of participants decreased their BMI. Most participants reported the program improved their ability to exercise regularly, eat a healthier diet and feel more self-confident. Peds QL™ psychosocial health domains increased postintervention. The YRBS showed increased physical activity and less sedentary time postintervention.Conclusions: This mobile app-based weight management program with coaching implemented may not be feasible for adoption in the general population of AYA with SB; however, it was well received by some, and further testing is needed to determine how to improve feasibility. This study provides useful information to guide future programs utilizing digital health and coaching.
Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing non-severe GPA. Patients who enter the trial will be maintained on a stable dose of their maintenance immunosuppressive agent which may include methotrexate (MTX), azathioprine (AZA), or mycophenolate (MA) and will undergo a blinded randomization to receive abatacept or placebo. Patients will additionally receive prednisone 30 mg daily that will then be tapered to zero using a standardized tapering schedule.

If an enrolled patient experiences a non-severe relapse or non-severe disease worsening though common closing, or if they have not achieved remission by month 6, they will have the option of entering an open-label trial period whereby they would receive abatacept in conjunction with their maintenance immunosuppressive and a standardized glucocorticoid taper. Patients with a severe disease relapse or severe disease worsening will have met criteria for early termination criteria and be removed from active study treatment. Patients will remain on study until reaching criteria for early termination or until common closing, 12 months after randomization of the final patient. After common closing or early termination, patients will be treated with best medical judgment and will undergo a post-treatment safety visit 3 months after coming off of study treatment.
BACKGROUND: Adenoid is a mass of lymphoid tissue seen in the posterior nasopharyngeal wall, generally seen in the pediatric age group, and it disappears as age advances till puberty. Patients with recurrent allergic rhinitis, otitis media, or persistent nasopharyngeal obstruction is associated with adenoid hypertrophy can be considered for adenoidectomy.
OBJECTIVE: To evaluate the potential role of Individualised Homeopathic medicine in managing allergic rhinitis and troublesome symptoms of upper respiratory tract in case of Enlarged adenoid.
METHOD: An 8-year-old boy came with complaints of Allergic rhinitis, snoring, and recurrent upper respiratory tract infection. He had taken treatment for the same from modern medicine, but still, a recurrence of symptoms occurred. His radiological investigations showed grade II Adenoid Hypertrophy. The patient was advised surgical intervention, but their parents were unwilling to the same so the patient came for Homoeopathic Management. Individualized Homeopathic Medicine Calcarea carbonicum 200 C was prescribed to the patient. The patient's condition significantly improved during the course of his five years of treatment; his snoring has decreased, his allergic manifestations have diminished, and monthly check-ups have revealed that the patient's general and particular condition are improving. indicating the positive result of homeopathic medicine in the treatment of enlarged adenoid. Assessment of outcome is based on Radiological reports and modified Naranjo criteria.
RESULT: Homoeopathic medicine Calcarea Carb 200 C is given to the patient based on the totality of symptoms. The incidence of allergic rhinitis has also declined following treatment. Furthermore, there has been a decrease in the grade of adenoid hypertrophy and a noticeable improvement in symptoms.
CONCLUSION: This is a single case where evidence shows that complete patient recovery occurs with individualized Homoeopathic Medicine. this is single case study and more researches, observational studies and randomized control trials are required to ascertain homeopathy's efficacy in managing enlarged Adenoids.
Provided herein are control and monitoring protocols for a virtual or augmented reality environment provided to patients, and which enable a trainer to have real-time monitoring and control of the virtual reality environment. In various embodiments, a virtual environment is provided to a first user at a first location. Data (e.g., biometric data) is collected based on the first user's interaction with the virtual environment while engaging in a training protocol. A real-time mirrored view of the virtual environment is provided to a second user via a network. The data and one or more control tools are provided to the second user. The control tools are configured to adjust one or more parameters of the virtual environment. A selection of at least one of the control tools is received form the second user and the virtual environment is adjusted based on the selection.
After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
Patients receive pidnarulex IV over 60 minutes on days 1 and 8 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tissue sample collection at baseline and on study, CT or MRI, and optionally undergo blood sample collection throughout the study.
This invention provides a method of inhibiting the binding of a .beta.-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding inhibiting amount of a compound capable of inhibiting binding of the .beta.-sheet fibril to RAGE so as to thereby inhibit binding of the .beta.-sheet fibril to RAGE. In one embodiment the .beta.-sheet fibril is amyloid fibril. In one embodiment, the compound is sRAGE or a fragment thereof. In another embodiment, the compound is an anti-RAGE antibody or portion thereof. This invention provides the above method wherein the inhibition of binding of the .beta.-sheet fibril to RAGE has the consequences of decreasing the load of .beta.-sheet fibril in the tissue, inhibiting fibril-induced programmed cell death, inhibiting fibril-induced cell stress. This invention also provides methods of determining whether a compound inhibits binding of a .beta.-sheet fibril to RAGE on the surface of a cell.
FIELD: medicine. SUBSTANCE: invention relates to agents based on biologically active substances of plant origin. Phytopreparation has 50-90 wt.-% alfalfa extract and filling agents - calcium gluconate, sucrose, calcium stearate and talc at amount 9.6-53.0 wt.-%. Preparation has no contraindications and adversive effects. Preparation can be used as an agent showing antiinflammatory, immunomodulating and anabolic effect. EFFECT: broadened pattern of preparation using, enhanced effectiveness. 9 tbl
BACKGROUND: Research on the effects of body mass index (BMI) on severe headache or migraine is limited and controversial. The aim of this study was to explore the association between BMI and the prevalence of migraine, with particular interest in diabetes status difference.
METHODS: The present study used analyzed data from people who participated in the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2004. Logistic regression models and restricted cubic spline (RCS) models were applied to investigate the relationship between body mass index and migraine.
RESULTS: A total of 10,074 adults aged 20 years or older were included in this study. Body mass index was positively related to migraine, and the corresponding odds ratio (OR; 95% CI) was 1.02 (1.01, 1.03; p < 0.001). And compared to participants in the lowest group of body mass index (< 25 kg/m2), the adjusted ORs for migraine in medium group (25-29.9 kg/m2), and highest group (≥ 30 kg/m2) were 1.14 (95% CI: 0.98-1.32, p = 0.09) and 1.30 (95% CI: 1.11-1.52, p = 0.0022), respectively. The relationship between BMI and migraine exhibited a linear in overall in the RCS. Our findings also suggested an interaction between BMI and diabetes. The relationship between BMI and migraine in adults with diabetes was non-linear. The OR of developing migraine was 1.30 (95% CI: 1.10-1.54) in individuals with BMI ≥ 29.71 kg/m2 in adults with diabetes.
CONCLUSION: A higher body mass index is significantly associated with an increased prevalence of migraine, and diabetes status can modify the association between them.
In the study group VRHD (Virtual Reality Hypnosis Distraction) 2, the patient received the VHRD technique for the first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score \>3).
Embodiments herein relate to hearing assistance devices and related systems and methods for providing visual feedback to a subject undergoing physical therapy or vestibular motor training. In an embodiment, a method of providing physical or vestibular treatment to a subject is included. The method may include prompting the subject to move a predetermined amount in a predetermined direction as part of a first predetermined movement. The method may further include tracking the motion of the subject using a first IMU disposed at a fixed position relative to the head of the subject. The method may further comprise generating feedback data by comparing the tracked motion of the subject to a predetermined direction and a predetermined amount of the first predetermined motion. The method may further include generating a feedback image using the feedback data. Other embodiments are included herein.
Patients with active, non-variceal, upper gastrointestinal bleeding usually need an urgent endoscopic treatment. The standard therapy by application of an hemoclip and/or injection of an epinephrine solution is not always successful. Bipolar hemostatic forceps is already being used successfully for the treatment of gastrointestinal bleeding in endoscopic submucosal dissection. Its use in primary endoscopic treatment of non-variceal, upper gastrointestinal bleeding has not been shown yet in a randomized prospective study. Patients with active, non-variceal, upper gastrointestinal bleeding (esophagus or stomach or duodenum) of any cause are randomized (1:1) in standard therapy by combination therapy using an hemoclip and/or injection of an epinephrine solution or experimental therapy by application of the bipolar hemostatic forceps. Cross over-treatment should be tried first in case of failed initial treatment. Rescue treatment by other methods such as application of an Over the Scope Clip (OTSC), angiographic embolization or surgery will be allowed next. All patients receive an additional standard therapy by proton pump inhibitors (PPI). Hypothesis: Endoscopic therapy by application of the bipolar hemostatic forceps is superior to standard therapy regarding technical success and rebleeding rate.
BACKGROUND: Patients with intermediate and high-risk oropharyngeal cancer (OPC) have poorer response to standard treatment and poorer overall survival compared to low-risk OPC. CompARE is designed to test alternative approaches to intensified treatment for these patients to improve survival.
METHODS: CompARE is a pragmatic phase III, open-label, multicenter randomised controlled trial with an adaptive multi-arm, multi-stage design and an integrated QuinteT Recruitment Intervention. Eligible OPC patients include those with human papillomavirus (HPV) negative, T1-T4, N1-N3 or T3-4, N0, or HPV positive N3, T4, or current smokers (or ≥ 10 pack years previous smoking history) with T1-T4, N2b-N3. CompARE was originally designed with four arms (one control [arm 1] and three experimental: arm 2-induction chemotherapy followed by arm 1; arm 3-dose-escalated radiotherapy plus concomitant cisplatin; and arm 4-resection of primary followed by arm 1). The three original experimental arms have been closed to recruitment and a further experimental arm opened (arm 5-induction durvalumab followed by arm 1 and then adjuvant durvalumab). Currently recruiting are arm 1 (control): standard treatment of 3-weekly cisplatin 100 mg/m2 or weekly 40 mg/m2 with intensity-modulated radiotherapy using 70 Gy in 35 fractions ± neck dissection determined by clinical and radiological assessment 3 months post-treatment, and arm 5 (intervention): one cycle of induction durvalumab 1500 mg followed by standard treatment then durvalumab 1500 mg every 4 weeks for a total of 6 months. The definitive and interim primary outcome measures are overall survival time and event-free survival (EFS) time, respectively. Secondary outcome measures include quality of life, toxicity, swallowing outcomes, feeding tube incidence, surgical complication rates, and cost-effectiveness. The design anticipates that after approximately 7 years, 84 required events will have occurred to enable analysis of the definitive primary outcome measure for this comparison. Planned interim futility analyses using EFS will also be performed.
DISCUSSION: CompARE is designed to be efficient and cost-effective in response to new data, emerging new treatments or difficulties, with the aim of bringing new treatment options for these patients.
TRIAL REGISTRATION: ISRCTN ISRCTN41478539 . Registered on 29 April 2015.
According to one embodiment, provided is a server which may receive reservation information from a terminal of a user. The server may identify a user and a hospital/clinic. The server may transmit reservation information to a second terminal of a second user based on the identified user and hospital/clinic. The server may receive the identification information of the user and the hospital/clinic from a terminal in which an application activated by an identifier corresponding to the hospital/clinic is installed. The server may transmit user information to the second terminal in response to the received identification information. The server may transmit the user information to the second terminal in response to the received identification information. The server may transmit the reception result to the terminal of the user based on the visit and waiting information of the hospital/clinic.
Blood-contact devices are prone to inflammation, endothelial dysfunction, coagulation, and the uncontrolled release of metal ions during implantation and service. Therefore, it is essential to make these multifunctional. Herein, a superhydrophobic DE@ZnS-ZnO@SA film (composed of dabigatran ester, zinc sulfite, zinc oxide, and stearic acid, respectively) is produced. The prepared film has non-adhesion and antibacterial properties, superior mechanical stability, durability, corrosion resistance, and is self-cleaning and blood-repellent. The results of the hemolysis, cytotoxicity, and other anticoagulant experiments revealed that the film had good blood compatibility, no cytotoxicity, and excellent anticoagulant properties. The film displays anticoagulant properties even after being immersed in Phosphate-Buffered Saline (PBS) for 7 days. Furthermore, the film can spontaneously release H2S gas for 90 h after soaking in an acidic environment (pH = 6) for 90 h. This property improves the acidic microenvironment of the lesion and promotes the proliferation of endothelial cells by using H2S gas. In addition, the film can inhibit the uncontrollable release of Zn2+ ions, avoiding its toxicity even when immersed in an acid environment for 35 days. This time-sequential functionalized surface has the potential to typify the future of blood-contacting scaffolds for long-lasting use.
BACKGROUND: Women carry a substantial burden of psychiatric, somatic and lifestyle-related morbidity in the prison context. By describing causes of death and estimating the risk and burden of mortality compared with the general population, this study investigates how mortality operates in this highly marginalized and under-researched population.
METHODS: In this registry-based study of all women incarcerated in Norwegian prisons from 2000 to 2019 (N = 11 313), we calculated crude mortality rates, years of lost life and, by using mortality in age-matched women from the general population as a reference, age-standardized mortality ratios and years of lost life rates.
RESULTS: Over a mean follow-up time of 10.7 years, at a median age of 50 years, 9% of the population had died (n = 1005). Most deaths (80%) were premature deaths from an avoidable cause. Drug-induced causes and deaths from major non-communicable diseases (NCDs) were most frequent (both 32%). Compared with women in the general population, women with a history of incarceration were more likely to die from any cause. Trends in annual age-standardized years of lost life rates suggest that the mortality burden associated with major NCDs has gradually replaced drug-induced causes.
CONCLUSIONS: Women with a history of incarceration die at a greater rate than their peers and largely from avoidable causes. The profile of causes contributing to the substantial burden of mortality placed on this population has changed over time and has important implications for future efforts to reduce morbidity and the risk of premature death following release from prison.